Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04620187 |
| Consolidated Lead Sponsor | Dana-Farber Cancer Institute |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 37 participants (ESTIMATED) |
| Registered Start Date | 2020-12-24 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Emory Winship Cancer Institute | Atlanta, GA | Open Hospital Dossier -> |
| University of Chicago Medicine | Chicago, IL | Open Hospital Dossier -> |
| Brigham and Women's Hospital | Boston, MA | Open Hospital Dossier -> |
| Dana-Farber Cancer Institute | Boston, MA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Dana-Farber Cancer Institute across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.